Analyst: Andrew Fein

Analyst

Andrew Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.

Continue reading “Analyst: Andrew Fein”

Article: H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

Article - Media

H.C. Wainwright Keeps Their Buy Rating on Insmed (INSM)

Jason Carr

AnalystRatings, 1 May 2020

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52.00. The company’s shares closed last Thursday at $23.00.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

Comment: This company is at risk of collusion between a placement agent and naked short sellers.

 

Article: Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Article - Media

Vertex Pharmaceuticals (VRTX) Receives a Buy from H.C. Wainwright

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Vertex Pharmaceuticals (), with a price target of $295.00. The company’s shares closed last Wednesday at $251.05.

According to TipRanks.com, Fein is a 5-star analyst with an average return of 8.9% and a 48.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.